alloplexbio.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $20.67MM
Alloplex Biotherapeutics is a biotechnology company that is developing novel, off-the-shelf allogeneic cell therapies for the treatment of cancer and other diseases. The company's proprietary platform, AlloCAR™, enables the engineering of T cells to express chimeric antigen receptors (CARs) that can recognize and attack tumor cells. Alloplex Biotherapeutics aims to transform the field of cell therapy by providing a scalable, cost-effective, and personalized approach to cancer treatment.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alloplex Biotherapeutics.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.